文献速递中医内科中药与中成药合理使用

丹参类注射液治疗急性冠脉综合征的多维贝叶斯网络Meta分析

Comparative Efficacy of Danshen Class Injections for Treating Acute Coronary Syndrome: A Multidimensional Bayesian Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2020-08-26

该研究采用贝叶斯网络Meta分析,系统检索多个数据库至2020年2月,纳入53项随机对照试验共6401例患者,比较不同丹参类注射液联合西药治疗急性冠脉综合征的疗效。结果显示丹参类注射液联合西药可显著提高临床有效率,多维聚类分析提示丹红注射液加西药与丹参注射液加西药疗效更优,但不良反应监测不足,安全性待进一步验证。

要点

  • 丹参类注射液联合西药较单用西药可显著提高急性冠脉综合征临床有效率。
  • 丹红注射液加西药与丹参注射液加西药在多维聚类分析中疗效更优。
  • 多数纳入试验未重点监测不良反应,安全性需进一步研究。

核心结论

  • 丹红注射液加西药与丹参注射液加西药可能对急性冠脉综合征患者有更好的疗效。
  • 未来仍需大样本、高质量、多中心随机对照试验验证。

研究设计与样本

  • 贝叶斯网络Meta分析,预先设定纳入与排除标准,系统检索多个数据库至2020年2月。
  • 共纳入53项随机对照试验,涉及6401例患者,采用WinBUGS 1.4.3、Stata V.13.0和R 3.6.1软件计算并做多维聚类分析。

主要发现

  • 与单用西药相比,丹参类注射液联合西药治疗与临床疗效显著改善相关。
  • 多维聚类分析显示丹红注射液加西药和丹参注射液加西药具有更好的治疗效果。
  • 多数纳入随机对照试验未关注不良反应监测,这些中药注射液的安全性需进一步探讨。

关键数值与推荐

  • 评估指标包括临床有效率、超敏C反应蛋白、C反应蛋白、白细胞介素-6、纤维蛋白原及不良反应。
  • 共纳入53项随机对照试验、6401例患者。

临床怎么用

  • 临床可考虑在急性冠脉综合征西药治疗基础上联用丹参类注射液以提高疗效。
  • 丹红注射液加西药与丹参注射液加西药可能为较优选择。
  • 使用丹参类注射液时应关注不良反应监测,安全性证据尚不充分。

局限性

  • 多数纳入随机对照试验未重点监测不良反应,安全性数据不足。
  • 需更多大样本、高质量、多中心随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute coronary syndrome, that is a common and serious cardiovascular disease, imposes a huge economic burden on global public health. And Danshen class injections are commonly used in the treatment of acute coronary syndrome in China. Thus, the Bayesian network meta-analysis was devised to investigate the efficacy of different Danshen class injections against acute coronary syndrome. METHODS: Eligible inclusion and exclusion criteria were established in advance. Then, a systematic literature search was performed in several databases from inception to February 2020. Further, the included randomized controlled trials data were adopted to calculation, prepare graphs and multidimensional cluster analysis by WinBUGS 1.4.3, Stata V.13.0 and R 3.6.1 software, respectively. RESULTS: A total of 53 eligible randomized controlled trial studies with 6401 patients were obtained that evaluated the clinical effectiveness rate, the level of hypersensitive C-reactive protein, C-reactive protein, interleukin-6, fibrinogen, and adverse reactions after the application of Danshen class injections plus western medicine. Compared with western medicine alone, Danshen class injections combined with western medicine therapy were associated with significantly improved the therapeutic effect. In addition, the results of the multidimensional cluster analysis demonstrated that Danhong injection + western medicine and Danshen injection + western medicine had better therapeutic effects. However, since most eligible randomized controlled trial studies did not focus on the monitoring of adverse reactions, the safety of these Chinese herbal injections needs to be further explored. CONCLUSION: Based on this Bayesian network meta-analysis results, Danhong injection + western medicine and Danshen injection + western medicine might have a better impact on acute coronary syndrome patients. Nevertheless, more large samples, high-quality clinical and multicenter randomized controlled trial studies should be tested and verified in the future.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Guo S, Wu J, Ni M, et al. Comparative Efficacy of Danshen Class Injections for Treating Acute Coronary Syndrome: A Multidimensional Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2020. PMID: 32982726. doi:10.3389/fphar.2020.01260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。